Skip to content
OpenCapital
Get started

Editas Medicine EDIT Q4 2025 Annual earnings

Reported March 9, 2026 · Before market open

Revenue$24.7MBeat by $16.4M
EPS-$0.06Beat by $0.21
Revenue estimate$8.3M
EPS estimate-$0.27

Next report

Aug 11, 2026 (In 1 week)
Revenue estimate$2.8M
EPS estimate-$0.30

Versus estimates

Revenue

Q1 2026$2.8MMiss by $3.5M
Q4 2025$24.7MBeat by $16.4M
Q3 2025$7.5MMiss by $910.8KQ2 2025$3.6MBeat by $1.8MQ1 2025$4.7MBeat by $4.0MQ4 2024$30.6MBeat by $30.0M

Diluted EPS

Q1 2026-$0.26Beat by $0.04
Q4 2025-$0.06Beat by $0.21
Q3 2025-$0.28Beat by $0.10Q2 2025-$0.63Miss by $0.22Q1 2025-$0.43Beat by $0.08Q4 2024-$0.55Miss by $0.16

Ask the moment Editas Medicine reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Editas Medicine report Q4 2025 earnings?
Editas Medicine (EDIT) reported Q4 2025 earnings on March 9, 2026 before market open.
What were Editas Medicine's Q4 2025 revenue and EPS?
Editas Medicine reported revenue of $24.7M and eps of $-0.06 for Q4 2025.
Did Editas Medicine beat estimates in Q4 2025?
Revenue beat the consensus estimate of $8.3M by $16.4M. EPS beat the consensus estimate of $-0.27 by $0.21.
How did Editas Medicine's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 19.2% from $30.6M a year earlier and eps grew 89.1% from $-0.55.
Where can I find Editas Medicine's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001650664-26-000013) and the 10-K periodic report (0001650664-26-000017) directly on SEC EDGAR. The filing index links above go to sec.gov.